

---

## Oncopeptides Q1 2025 - Strong Q/Q Growth with Japan the Next Catalyst

Redey comments on Oncopeptides' first quarter report 2025. The growth quarter on quarter was 34%, despite a 5% FX headwind. Discussions about a potential deal in Japan are still ongoing. We believe the sales growth trend is stabilising with growing uptake from new markets.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Oncopeptides Q1 2025 - Strong Q/Q Growth with Japan the Next Catalyst**